LATAM MedTech Insights

Ran Chen
  • 0.0 (0)
  • CIENCIAS DE LA VIDA

Welcome to LATAM MedTech Insights, your essential guide to the booming medical technology and digital health sector across Latin America. Each episode, we dissect the key trends, investment opportunities, and regulatory news shaping the industry. Join us for in-depth interviews with the innovators, investors, and policymakers driving the future of healthcare from Mexico to Brazil.

  1. HACE 3 H

    Pure Global: Costa Rica's MedTech Gambit - The New Local-Only Fast Track

    This week, we dive into a game-changing development out of Costa Rica. Long known as a premier manufacturing hub for MedTech, the country just launched the "Medical Device Innovation Pathway" (MDIP), a new accelerated registration process exclusively for locally manufactured devices. This move could redefine market entry strategies across Latin America, offering unprecedented speed but with significant new hurdles. We unpack what the MDIP truly entails, moving beyond the headlines to analyze the specific, challenging requirements hidden within this new regulation. This episode is essential for any MedTech leader who manufactures in, or is considering, Costa Rica as a strategic base for their LATAM operations. Case Study: Imagine you've invested millions in a state-of-the-art manufacturing facility in Costa Rica. The new MDIP promises a rapid launch into the LATAM market, but it comes with surprise local audits and stringent data-sharing clauses that your global compliance framework is not prepared for. Is this accelerated pathway a golden opportunity or a regulatory trap? What you will learn: - What are the specific terms of Costa Rica's new Medical Device Innovation Pathway? - Why is this new regulation a strategic "gambit" for the country's economy? - What are the top three hidden compliance traps in the new fast-track process? - How do the MDIP's quality system requirements differ from ISO 13485? - Could this "local-first" regulatory model be adopted by other LATAM countries? - How will this impact decisions for siting new manufacturing facilities in the region? - What are the critical questions to ask your regulatory team about this development today? At Pure Global, we specialize in turning complex regulatory challenges into clear market access strategies. Our team of local experts in Latin America provides on-the-ground support for everything from initial regulatory strategy and technical dossier submission to quality assurance and post-market surveillance. We help you navigate intricate local requirements like Costa Rica's MDIP, ensuring your path to market is both fast and compliant. Don't let regulatory surprises derail your launch. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

    2 min

  2. HACE 1 DÍA

    Pure Global: Brazil's ANVISA Shift – Cracking the Code of the New RDC 751 Landscape.

    This week, we dissect the latest critical guidance from Brazil's ANVISA on RDC 751, a regulation that aligns the country's medical device framework with the EU's MDR. This is more than a policy update. it's a strategic shift that redefines the requirements for market access in Latin America's powerhouse. We explore the immediate impact on technical dossiers, post-market surveillance, and the newly empowered role of the Brazil Registration Holder. This episode is for any MedTech manufacturer eyeing the Brazilian market. We break down the hidden complexities and strategic opportunities this presents. Imagine a global scale-up, already EU MDR approved, that believed its entry into Brazil would be seamless. They are now facing unexpected delays and costly rework because their technical file missed nuanced local requirements hidden within the new guidance. Their entire product launch is at risk. Key questions from this episode include: - Is your current technical file truly ready for ANVISA's new dossier structure? - How does the new risk classification system impact your device registration timeline? - What are the unwritten rules for post-market surveillance that ANVISA now expects? - Could your existing EU MDR strategy create unforeseen compliance gaps in Brazil? - Are you prepared for the expanded liability now placed on your Brazil Registration Holder? - What specific labeling and instruction-for-use changes are required immediately? - How can you leverage local representation to accelerate the new review process? Pure Global offers end-to-end regulatory consulting solutions for Medical Technology (MedTech) and In-Vitro Diagnostic (IVD) companies, combining local expertise with advanced AI and data tools to streamline global market access. Contact Pure Global at info@pureglobal.com or visit us at https://pureglobal.com/.

    2 min

  3. HACE 2 DÍAS

    Brazil's AI MedTech Surprise: Pure Global on ANVISA's New Rulebook & Hidden Data Traps

    This week on LATAM MedTech Insights, we dissect the groundbreaking new regulatory framework released by Brazil's ANVISA for AI-powered medical devices. Announced just last week, this move positions Brazil as a leader in digital health regulation in Latin America, but it also creates significant new hurdles for innovators looking to enter the market. We explore the specific requirements of the new resolution, including the critical and non-negotiable need for clinical data from the local Brazilian population. This change has immediate implications for international companies, potentially delaying market entry and adding significant costs. Understanding the nuances of this regulation is now the key to unlocking the Brazilian MedTech market. A real-world pain point: Imagine your company has developed a revolutionary AI diagnostic tool, validated with world-class data from the US and Europe. You're ready to launch in the massive Brazilian market, but ANVISA's new rule means your existing data is suddenly insufficient. You now face an unexpected 18-month delay and the seven-figure cost of running a new local clinical trial. This is the exact, urgent challenge companies are grappling with right now. Key Takeaways This Episode: 1. What are the specific risk classifications for AI software under ANVISA's new resolution? 2. Why is local Brazilian population data now a mandatory requirement for regulatory approval? 3. What is the compliance deadline for AI-powered devices that are already on the market? 4. How does this regulatory shift impact the investment landscape for digital health startups in Brazil? 5. Are other major LATAM markets like Mexico and Colombia expected to follow Brazil's lead? 6. What are the essential new components you must include in your technical dossier for a successful submission? 7. How can you strategically leverage this regulatory change as a competitive advantage instead of seeing it as a roadblock? Navigating complex regulatory shifts like this is what we do best. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining deep local expertise in markets like Brazil with advanced AI tools to streamline your global market access. Don't let regulatory hurdles block your innovation. Contact Pure Global for a strategic consultation at info@pureglobal.com or visit us at https://pureglobal.com/.

    2 min

  4. HACE 3 DÍAS

    Pure Global: Brazil's MedTech Renewal Riddle - Cracking ANVISA's New 10-Year Cycle.

    This week on LATAM MedTech Insights, we dissect a game-changing update from Brazil's regulatory agency, ANVISA. The validity for medical device registrations has been doubled from five to ten years. This sounds like great news, but it comes with a significant new hurdle: a mandatory mid-cycle compliance review that could catch unprepared companies off guard. We break down what this shift means for your long-term strategy in Latin America's biggest market. We explore the opportunities for reduced administrative burden and the hidden risks associated with the new, more stringent post-market surveillance requirements that underpin this extended registration period. Imagine your Class III device registration in Brazil is suddenly suspended five years into its new ten-year term. Your sales are frozen. This is the risk for manufacturers who misunderstand the new mid-cycle review. We discuss how to avoid this scenario by implementing a proactive compliance strategy from day one. Key Takeaways: - What specific documentation is required for ANVISA's new mid-cycle review? - How does the 10-year registration impact the role and responsibilities of a local Brazilian Registration Holder? - What are the biggest mistakes foreign manufacturers can make when adapting to this new regulation? - How should your Quality Management System be updated to handle continuous surveillance versus periodic renewal? - Does this change signal a wider trend towards longer registration cycles in other LATAM markets? - What are the specific post-market surveillance data points ANVISA will now scrutinize more closely? - How can you leverage this regulatory change to gain a competitive advantage in Brazil? At Pure Global, we provide the local expertise and strategic guidance to navigate these complex regulatory shifts. We offer end-to-end solutions, from initial market access strategy and technical dossier submission to managing your post-market surveillance and acting as your official in-country representative. To secure your market presence in Brazil and beyond, contact us at info@pureglobal.com or visit https://pureglobal.com/.

    2 min

  5. HACE 4 DÍAS

    Pure Global: Brazil's ANVISA Deadline Chaos - A Survival Guide for MedTech.

    Last week, Brazil's ANVISA sent shockwaves through the MedTech industry by announcing a hard deadline for transitioning all medical device registrations to the new RDC 751 framework. In this episode, we break down what this sudden enforcement means for foreign manufacturers, moving beyond the headlines to reveal the hidden complexities and strategic risks. We explore why existing international dossiers, like those for CE marking, may not be enough and what specific gaps ANVISA is targeting, putting your market access in jeopardy. We examine the case of a European orthopedic implant company whose Brazilian sales were abruptly halted. Discover the critical flaw in their post-market surveillance plan that satisfied EU regulators but failed ANVISA's new, stricter review, forcing them into a costly and time-consuming remediation process. Key Takeaways for This Episode: 1. What is the number one mistake companies make when adapting their technical file for RDC 751? 2. Are your existing risk management and clinical evaluation reports truly compliant with Brazil's new requirements? 3. How can you avoid the common pitfalls that lead to registration suspension during this transition? 4. What specific labeling changes does ANVISA now require that could impact your supply chain? 5. Does your Brazil Registration Holder (BRH) have the technical expertise to defend your new dossier? 6. How will this surprise deadline impact your product launch timeline in Brazil for the next year? Don't let regulatory hurdles in Latin America derail your growth. Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise and advanced AI tools to streamline market access. From developing a robust regulatory strategy for Brazil to acting as your official in-country representative, we ensure your products meet ANVISA's demanding standards. Contact us to secure your market presence at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

    2 min

  6. HACE 5 DÍAS

    Mexico's Digital Gate: Pure Global on COFEPRIS's Chaotic New Platform.

    Mexico's regulatory authority, COFEPRIS, has just launched its mandatory all-digital submission platform, DigiPRIS. While this move promises to streamline market access, the initial rollout has created significant and unexpected challenges for medical device manufacturers, leading to submission errors, delays, and uncertainty. This episode of LATAM MedTech Insights unpacks the chaotic first week of the new system. We share a real-world case study of a cardiovascular device company whose complete digital submission vanished from the COFEPRIS portal without a trace after being successfully uploaded. This costly setback highlights the critical need for navigating the platform's undocumented requirements and technical instability. Key Takeaways in this episode: - What are the unwritten rules and hidden formatting requirements of the new DigiPRIS platform? - How can you verify your digital submission is secure and correctly processed by COFEPRIS? - What is the new timeline for approvals, and how does the digital system impact it? - Which device classes are most affected by the platform's initial instability? - What is the most effective way to communicate with COFEPRIS about a digital submission error? - How should you adapt your regulatory strategy to mitigate the risks of this digital transition? - Are there new cybersecurity concerns for your technical dossier on the DigiPRIS platform? At Pure Global, we specialize in navigating these complex regulatory shifts. Our local experts in Mexico combined with our advanced AI tools provide the real-time support needed to overcome digital barriers and ensure your product gets to market efficiently. Don't let digital chaos derail your launch. Contact Pure Global at info@pureglobal.com or visit https://pureglobal.com/.

    2 min

  7. HACE 6 DÍAS

    Pure Global's Brazil Brief: Decoding ANVISA's New AI Rules for MedTech Innovators.

    In this episode, we dive into a critical regulatory update from Brazil that is sending shockwaves through the digital health community. Last week, ANVISA unexpectedly released a new instruction specifically targeting AI and Software as a Medical Device (SaMD), creating immediate hurdles for foreign manufacturers. We break down the three core changes involving clinical data, cybersecurity, and algorithm updates. This shift presents a major challenge for companies relying on international data and standard privacy protocols for their market entry. **Case In Point:** A German AI diagnostics firm, fully prepared for its Brazilian launch with a complete EU-validated data package, now faces a mandatory, year-long delay. They must initiate a new, costly local clinical study and re-engineer their data systems to comply with Brazil's specific privacy laws, jeopardizing their entire LATAM expansion strategy. **In this episode, you will learn:** * What are the specific new clinical data requirements for AI devices in Brazil? * How does Brazil's LGPD law now directly impact SaMD cybersecurity protocols? * Why might your existing FDA or CE mark for an AI device be insufficient for ANVISA? * What is the new, burdensome process for submitting simple algorithm updates? * Is it now impossible to enter the Brazilian market without local clinical trials? * Which types of SaMD are most affected by this surprise regulation? * What are the immediate steps you should take if you are planning a launch in Brazil? At Pure Global, we offer end-to-end regulatory consulting to help MedTech innovators navigate complex markets like Brazil. We combine local expertise with advanced AI tools to streamline global market access, from regulatory strategy and dossier submission to acting as your official in-country representative. To turn regulatory hurdles into market opportunities, contact us at info@pureglobal.com or visit https://pureglobal.com/.

    2 min

  8. 16 ABR

    Pure Global: Brazil's New ANVISA Gambit - Cracking the Code on Fast-Track Registration

    This week, we dive into a sudden and pivotal regulatory shift in Brazil. ANVISA has just launched a new fast-track approval pathway for medium-risk medical devices, a move that could dramatically accelerate market entry. But this opportunity comes with a complex new requirement that is already tripping up unprepared manufacturers. In this episode, we break down exactly what ANVISA's new resolution entails. We explore the case of a German MedTech firm whose attempt to leverage this new fast-track process was immediately halted by a documentation mistake, highlighting a critical new pain point for foreign companies. This is a must-listen for any regulatory professional eyeing the Brazilian market. Key Questions from This Episode: - Does your existing FDA or CE clearance automatically qualify you for ANVISA's new fast-track process? - What is the single most common error companies are making in the new 'Comparative Regulatory Analysis' report? - How can you leverage your existing technical file to meet the stringent new local requirements in Brazil? - Why might your standard global registration strategy fail under this new Brazilian rule? - What specific expertise is now essential for a successful and speedy submission to ANVISA? - Is it possible to get your device approved in Brazil in under six months, and what's the secret? Navigating global markets requires more than just a great product; it demands flawless regulatory execution. At Pure Global, we provide end-to-end regulatory consulting, acting as your local representative in over 30 markets, including Brazil. We combine local expertise with advanced AI tools to streamline market access, manage technical dossiers, and ensure your submission is right the first time. Don't let regulatory hurdles block your expansion. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

    2 min
Ver todo (175)

Acerca de

Welcome to LATAM MedTech Insights, your essential guide to the booming medical technology and digital health sector across Latin America. Each episode, we dissect the key trends, investment opportunities, and regulatory news shaping the industry. Join us for in-depth interviews with the innovators, investors, and policymakers driving the future of healthcare from Mexico to Brazil.

Información

  • Creador
    Ran Chen
  • Años de actividad
    2025 - 2026
  • Episodios
    175
  • Clasificación
    Apto
  • Copyright
    © Copyright 2026 Ran Chen
  • Mostrar sitio web
    LATAM MedTech Insights